Compare AWX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | SKYE |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.0M |
| IPO Year | 1998 | 2013 |
| Metric | AWX | SKYE |
|---|---|---|
| Price | $2.56 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 8.9K | ★ 516.4K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,090,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $2.43 | $0.26 |
| 52 Week High | $5.43 | $4.99 |
| Indicator | AWX | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 68.24 |
| Support Level | $2.47 | $0.66 |
| Resistance Level | $2.56 | $2.32 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.00 | 65.57 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment, which is the key revenue driver, provides hazardous and non-hazardous brokerage and management services to industrial, commercial, municipal, and governmental customers, captive landfill management for an industrial customer, and saltwater injection well operations. Its Golf and related operations segment consists of four golf courses and associated clubhouses, which provide dining and banquet facilities, a hotel which provides lodging and resort-related amenities.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.